ABVC Biopharma Inc • ABVC

Capital at risk.

About ABVC Biopharma Inc
Ticker
info
ABVC
Trading on
info
NASDAQ
ISIN
info
US00091F1066
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Uttam Yashwant Patil Ph.D.
Headquarters
info
44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538
Employees
info
16
Website
info
abvcpharma.com
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Metrics
BasicAdvanced
Market cap
info
$16.7M
P/E ratio
info
-
EPS
info
-$0.81
Dividend Yield
info
0.00%
Beta
info
0.67
Forward P/E ratio
info
0
EBIDTA
info
$-6.3M
Ex dividend date
info
-
Price & volume
Market cap
info
$16.7M
Average daily volume
info
0.2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
32.77
Price to book
info
1.95
Earnings
EPS
info
-$0.81
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-6.3M
Revenues (TTM)
info
$0.5M
Revenues per share (TTM)
info
$0.05
Technicals
Beta
info
0.67
52-week High
info
$1.73
52-week Low
info
$0.40
50-day moving average
info
$0.59
200-day moving average
info
$0.64
Short ratio
info
0.24
Short %
info
1.54%
Management effectiveness
ROE (TTM)
info
102.32%
ROA (TTM)
info
25.30%
Profit margin
info
0.00%
Gross profit margin
info
$0.4M
Operating margin
info
17.16%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
2,350.70%
Share stats
Outstanding Shares
info
23.7M
Float
info
9.4M
Insiders %
info
21.95%
Institutions %
info
3.89%
Analyst Insights & forecasts
info

0% Buy

100% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$2.02
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.39
-
-
Q4 • 23Beat
-$0.40
-
-
Q1 • 24Beat
-$0.09
-
-
Q2 • 24Beat
-$0.02
-
-
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0.1M
$-1M
864.46%
Q2 • 24
$0.4M
$-0.2M
47.93%
Q3 • 24
232.31%
81.58%
94.46%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$14.6M
$6.8M
46.51%
Q2 • 24
$14.5M
$6.5M
44.83%
Q3 • 24
1.17%
4.73%
3.60%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-1M
-
$0.9M
$-1M
Q2 • 24
$0.2M
$0M
$-0.1M
$0.2M
Q3 • 24
116.93%
-
116.74%
116.93%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a ABVC Biopharma Inc share?
Collapse

ABVC Biopharma Inc shares are currently traded for undefined per share.

How many shares does ABVC Biopharma Inc have?
Collapse

ABVC Biopharma Inc currently has 23.7M shares.

Does ABVC Biopharma Inc pay dividends?
Collapse

No, ABVC Biopharma Inc doesn't pay dividends.

What is ABVC Biopharma Inc 52 week high?
Collapse

ABVC Biopharma Inc 52 week high is $1.73.

What is ABVC Biopharma Inc 52 week low?
Collapse

ABVC Biopharma Inc 52 week low is $0.40.

What is the 200-day moving average of ABVC Biopharma Inc?
Collapse

ABVC Biopharma Inc 200-day moving average is $0.64.

Who is ABVC Biopharma Inc CEO?
Collapse

The CEO of ABVC Biopharma Inc is Dr. Uttam Yashwant Patil Ph.D..

How many employees ABVC Biopharma Inc has?
Collapse

ABVC Biopharma Inc has 16 employees.

What is the market cap of ABVC Biopharma Inc?
Collapse

The market cap of ABVC Biopharma Inc is $16.7M.

What is the P/E of ABVC Biopharma Inc?
Collapse

The current P/E of ABVC Biopharma Inc is null.

What is the EPS of ABVC Biopharma Inc?
Collapse

The EPS of ABVC Biopharma Inc is -$0.81.

What is the PEG Ratio of ABVC Biopharma Inc?
Collapse

The PEG Ratio of ABVC Biopharma Inc is null.

What do analysts say about ABVC Biopharma Inc?
Collapse

According to the analysts ABVC Biopharma Inc is considered a hold.